Nyxoah (NASDAQ:NYXH) Price Target Lowered to $8.00 at Stifel Nicolaus

Key Points

• Stifel Nicolaus cut Nyxoah's price target from $10 to $8 but kept a "buy" rating, implying about a 177% upside from the current share price.
• Analyst coverage is mixed — three Buys versus one Sell — resulting in a consensus rating of Moderate Buy and a consensus price target of $9.33.
• Shares trade around $2.89 with a market cap near $112M, while the company reports negative EPS and margins (EPS -$0.69 last quarter) and a 52‑week range of $2.76–$8.64.

Nyxoah (NASDAQ:NYXH - Get Free Report) had its price target dropped by investment analysts at Stifel Nicolaus from $10.00 to $8.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price target suggests a potential upside of 177.30% from the company's current price.

NYXH has been the subject of several other reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $11.00 target price on shares of Nyxoah in a research note on Monday, March 23rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Nyxoah in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nyxoah currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.33.

Nyxoah Stock Performance

Shares of NYXH traded up $0.02 during trading hours on Friday, hitting $2.89. The stock had a trading volume of 2,162 shares, compared to its average volume of 54,071. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.16 and a current ratio of 1.25. The firm has a 50-day moving average price of $3.84 and a 200 day moving average price of $4.63. Nyxoah has a fifty-two week low of $2.76 and a fifty-two week high of $8.64. The firm has a market capitalization of $111.82 million, a price-to-earnings ratio of -1.08 and a beta of 1.66.

Nyxoah (NASDAQ:NYXH - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($0.69) earnings per share (EPS) for the quarter. Nyxoah had a negative net margin of 884.69% and a negative return on equity of 139.18%. The firm had revenue of $6.62 million during the quarter. As a group, research analysts anticipate that Nyxoah will post -1.91 EPS for the current year.

Hedge Funds Weigh In On Nyxoah

Large investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. raised its position in Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company's stock worth $59,000 after acquiring an additional 3,353 shares during the period. Heights Capital Management Inc. acquired a new position in Nyxoah during the fourth quarter worth $3,575,000. Shay Capital LLC acquired a new position in Nyxoah during the second quarter worth $374,000. Deutsche Bank AG raised its position in Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company's stock worth $161,000 after acquiring an additional 10,000 shares during the period. Finally, Citadel Advisors LLC acquired a new position in Nyxoah during the third quarter worth $98,000.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company's primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.